You are currently viewing Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

In this Issue

  • atai Sells a Third of Compass Stake to Raise Cash for In-House Programs
  • Lykos’ Unproven Psychotherapy Hampered Studies, Claim Authors of New Viewpoint
  • Picking Placebos for Psychedelic Studies
  • Small Study of Psilocybin in Severe TRD Among Veterans Shows Promise, But Authors Encourage Tempering Expectations
  • More Headlines

***

atai Sells a Third of Compass Stake to Raise Cash for In-House Programs

SEC filings reveal that last week atai Life Sciences disposed of around 2.7 million Compass Pathways shares for gross proceeds of just over $16 million. That represents around a third of atai’s stake in Compass.

The sale comes as Compass is expected to share a first cut of data from its Phase 3 program of its psilocybin candidate (COMP360) for treatment-resistant depression, which could be announced by the end of the calendar year or in Q1’25.

But it doesn’t appear that atai’s disposal signals wavering confidence in Compass’ Phase 3 program: atai CFO Anne Johnson told Psychedelic Alpha that the company did so to raise funds for the development of its in-house programs.

With a 10.1% stake left in Compass, according to filings, Johnson told us that atai remains a firm supporter of Compass, and has “high conviction in their ongoing COMP005 and COMP006 Phase 3 studies.” Indeed, writing on LinkedIn and Twitter, atai founder Christian Angermayer said that the company “continues to be a strong supporter of the excellent work of Compass”.

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…

Join Pα+ Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.


Already a member? Log In


   Regular Bulletins covering key topics and trends in the psychedelics space
   Regular articles and deep dives across psychedelic research, policy and business
   Interviews with insiders
   Monthly interactive database and commentary on psychedelic patents
   Quick-take analysis of major developments
   A Library of primers and explainers
   Access to our full back catalogue


Learn more about Pα+